Category Archive for: ‘Patents’

#BIO2018: Gene therapy, AI in healthcare, precision medicine and Diana Ross – The power of biotechnology

As we wrap up our week of insights on the biotech industry and coverage of #Bio2018, what is clear is that for many biotech innovations, the story is just beginning. From landmark developments in genetic engineering techniques, the integration of AI and digital technologies into health care products and services and the increasing investment in genomics based medicine, perhaps the …

Read More
Subjects:

Gene editing and genetic engineering techniques

Continuing our series on biotechnology for #Bio2018, this post looks at the development of new gene editing and genetic engineering techniques – a key trend shaping the biotechnology industry.   New genome editing techniques, such as CRISPR/Cas9, have made editing genomic material cheap, efficient and accessible.  These new techniques have opened up a plethora of opportunities for scientific progress previously considered …

Read More
Subjects:

#BIO2018: KWM report from the Bio 2018 Convention

Couldn’t make it to #Bio2018? This week, Anna Feros reports on her insights from the BIO International Convention in Boston, hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations.  The first full day at BIO2018 kicked off with an inspirational keynote session led by BIO president, Jim Greenwood, who …

Read More
Subjects:

How AI is shaping healthcare

As keepers of the world’s ‘big data’, many of the major tech companies  are naturally well placed to turn to the data-hungry development of artificial intelligence, or AI.  And while AI is a hot topic in almost every industry, its presence and potential application in healthcare is exploding. AI – what is it exactly? In the simplest sense, AI is …

Read More
Subjects: | |

The final word and ‘smoking gun’ documents – ACCC v Pfizer

For those readers interested in the issues surrounding competitive moves by pharmaceutical companies in the scenario where a key patent comes to an end, we report on the recent decision of the Full Federal Court in the ACCC v Pfizer matter here: ACCC v Pfizer – KWM News & Insights

Read More

Is the cure in your DNA? – The rise of biopharmaceuticals and pharmacogenomics-led therapy

15 years has passed since the Human Genome Project, involving the identification and mapping of all the genes of the human genome, was declared complete. Work on the project (which formally started in 1990 and spanned 15 years) involved international collaboration between scores of scientific researchers and funding of ~US$3 billion. As one of the world’s greatest collective scientific endeavours, …

Read More

Biotech Insights: 2018 industry snapshot and key trends

With the latest Scientific American, Worldwide Scorecard ranking Australia in the top five bio-economies globally, Australia’s biotechnology and life sciences sector continues to show healthy performance for the fifth consecutive year.  Despite the challenges of the global economy, there has been generally positive sentiment from an industry that is expected to continue growing, reaching close to $8B in revenue over …

Read More

Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China

Chinese and Australian businesses looking for overseas opportunities to expand in the healthcare industry should be aware of important regulatory changes that are taking place in both China and Australia. The healthcare industry in both Australia and China is undergoing significant growth that has been accompanied by rapid regulatory change. Both countries have invested significantly in the industry which increasingly …

Read More
Subjects:

Second throw of the dice unsuccessful: Full Federal Court confirms Hepatitis C drug patent is invalid

The recent decision of the Full Court in Idenix Pharmaceuticals v Gilead Sciences [2017] FCAFC 196 illustrates the power of the grounds of lack of utility and lack of sufficiency under section 40 of the Patents Act when challenging the validity of a patent. The decision concerned lack of utility and lack of sufficiency as those grounds existed prior to the introduction …

Read More
Subjects:

Page 1 of 2812345»1020...Last »